CRIBA VIBRATORIA INCLINADA DE DESPOLVE DE 3' X 10' DOS CAMAS. Con flecha contrapesos en acero 1045, montada en baleros de doble hilera de rodillos; tapas laterales en placa de 5/16" A 36; bastidores de camas construidos en canal de 4" atornillados a los laterales; suspensión de RESORTES AHULADOS EXCLUSIVOS DE ROCK-DOG; motor de 15 H.P ...
open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 19:295–309 2. Leon-CastilloA,deBoerSM,PowellME,MileshkinLR,MackayHJ, Leary A, Nijman HW et al (2020) Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol 38:3388–3397 3.
Canal Bridas Paralelas en Acero Inox MC 6X16 3 está disponible en perfiles laminados en caliente y con fusion láser. Las formas, tamaños y aleaciones personalizados están disponibles bajo pedido. ... 16.3. Producción: Fundido por Láser. Acabado: Granallado y Decapado. Disponibilidad: Bajo demanda. Longitud en existencia: 20. Productos ...
The PORTEC 3 study was supported in the UK by CRUK (C7925/A8659). Participation in the PORTEC-3 trial by ANZGOG and TROG were supported by the NHMRC Project Grant 570894 (2008) and by a Cancer Australia Grant (awarded through the 2011 round of the Priority-driven Collaborative Cancer Research Scheme and funded by Cancer Australia).
PORTEC-3 is registered with ISRCTN, number ISRCTN14387080, and ClinicalTrials.gov, number NCT00411138. RESULTS. 686 women were enrolled between Nov 23, 2006, and Dec 20, 2013. 660 eligible patients were included in the final analysis, of whom 330 were assigned to chemoradiotherapy and 330 were assigned to radiotherapy. Median follow-up was 60 ...
The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy during and after radiotherapy (chemoradiotherapy) versus pelvic radiotherapy alone for women with high-risk endometrial cancer. Methods PORTEC-3 was an open-label, international, randomised, phase 3 trial involving 103 centres in six clinical
PORTEC-3 is registered with ISRCTN, number ISRCTN14387080, and ClinicalTrials.gov, number NCT00411138. Results: 686 women were enrolled between Nov 23, 2006, and Dec 20, 2013. 660 eligible patients were included in the final analysis, of whom 330 were assigned to chemoradiotherapy and 330 were assigned to radiotherapy. Median follow-up was 60 ...
PORTEC-3 is registered with ISRCTN (ISRCTN14387080) and ClinicalTrials.gov (NCT00411138). Results: 686 women were enrolled between 2006 and 2013. 26 women were excluded; 13 withdrew consent early and 13 were ineligible, which left 660 patients in the analysis, with a median follow up time of 60.2 months (IQR 47.1–72.9): 330 CTRT and 330 RT.
Disease Site: High-risk endometrial cancer Publication Title: Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial Year of Publication: 2018 Hypothesis: The study hypothesized that adjuvant …